Eisai Co., Ltd.

This study tests a new drug (E7389 liposomal) combined with an immunotherapy (nivolumab) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 125 adults with ce…

This early-phase study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study includes people with several cancer types…

This early-phase study tests a new drug called E7090, alone or with other cancer medicines, in people with a certain type of advanced breast cancer (ER+, HER2-). The main goal is to find safe doses and check for side effects. About 51 participants will take part to help guide fut…

This early-phase study tests the safety and tolerability of a new drug called E7386 in 70 people with advanced solid tumors, including colorectal cancer. Participants have tumors that cannot be removed by surgery or have come back, and no standard treatments are available. The ma…

This study looks at the safety of the drug tazemetostat in 145 people in Japan who have a type of lymphoma (follicular lymphoma) that has come back or stopped responding to treatment and who have a specific gene change (EZH2 mutation). The study does not give any new treatment—it…